United Therapeutics Chairperson, CEO Martine A. Rothblatt reports disposal of common shares worth $4.4 million

By Public Technologies
  • United Therapeutics Chairperson, CEO Martine A. Rothblatt reported option exercise, acquiring 9,500 common shares at USD 117.76.
  • Family trust then sold 9,500 shares in multiple trades at weighted-average prices from USD 488.6962 to USD 500.05.
  • Trust holdings in common stock fell to 324,443 shares following the transactions dated Sept. 23.
  • Trust-held stock options increased to 375,910 following the exercise.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000148), on September 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.